Merck’s Lagevrio (molnupiravir) Missed Primary Endpoints in P-III Trial (MOVe-AHEAD) for Post-Exposure Prophylaxis to Prevent COVI...
Shots: The P-III trial (MOVe-AHEAD) evaluating Lagevrio (800mg) vs PBO in 1500 pat...
Novavax Initiates P-II Trial of COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates
Shots: The company initiates the P-II trial, conducted in 2 parts evaluating the c...
Junshi Biosciences Reports P-III Clinical Trial Results of VV116 for Severe COVID-19
Shots: The P-III trial results published in
Jiangsu Recbio Technology Reports P-II Study Results of Two-Component COVID-19 Vaccine ReCOV
Shots: The P-II study evaluating the immunogenicity & safety profile of recomb...
Novavax’s Nuvaxovid Receives Expanded Authorization for COVID-19 in Canada
Shots: Nuvaxovid (NVX-CoV2373) received expanded authorization from Health Canada...
Pfizer and BioNTech Reports P-II/III Trial Results of Omicron BA.4/BA.5-Adapted Bivalent Booster for COVID-19
Shots: The P-II/III trial to evaluate Omicron BA.4/BA.5-Adapted Bivalent Booster (...
